404 related articles for article (PubMed ID: 27194023)
1. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.
Cannon JA; Shen L; Jhund PS; Anand IS; Komajda M; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2016 Aug; 18(8):1021-31. PubMed ID: 27194023
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
Komajda M; Carson PE; Hetzel S; McKelvie R; McMurray J; Ptaszynska A; Zile MR; Demets D; Massie BM
Circ Heart Fail; 2011 Jan; 4(1):27-35. PubMed ID: 21068341
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
[TBL] [Abstract][Full Text] [Related]
5. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
[TBL] [Abstract][Full Text] [Related]
6. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
[TBL] [Abstract][Full Text] [Related]
7. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
[TBL] [Abstract][Full Text] [Related]
8. New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resychronization therapy.
Braunschweig F; Linde C; Benson L; Ståhlberg M; Dahlström U; Lund LH
Eur J Heart Fail; 2017 Mar; 19(3):366-376. PubMed ID: 27338764
[TBL] [Abstract][Full Text] [Related]
9. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
Böhm M; Perez AC; Jhund PS; Reil JC; Komajda M; Zile MR; McKelvie RS; Anand IS; Massie BM; Carson PE; McMurray JJ;
Eur J Heart Fail; 2014 Jul; 16(7):778-87. PubMed ID: 24864045
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE.
Kristensen SL; Castagno D; Shen L; Jhund PS; Docherty KF; Rørth R; Abraham WT; Desai AS; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Eur J Heart Fail; 2020 Dec; 22(12):2370-2379. PubMed ID: 32720404
[TBL] [Abstract][Full Text] [Related]
11. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
[TBL] [Abstract][Full Text] [Related]
12. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
Haass M; Kitzman DW; Anand IS; Miller A; Zile MR; Massie BM; Carson PE
Circ Heart Fail; 2011 May; 4(3):324-31. PubMed ID: 21350053
[TBL] [Abstract][Full Text] [Related]
13. Irbesartan in patients with heart failure and preserved ejection fraction.
Massie BM; Carson PE; McMurray JJ; Komajda M; McKelvie R; Zile MR; Anderson S; Donovan M; Iverson E; Staiger C; Ptaszynska A;
N Engl J Med; 2008 Dec; 359(23):2456-67. PubMed ID: 19001508
[TBL] [Abstract][Full Text] [Related]
14. The relationship of QRS morphology with cardiac structure and function in patients with heart failure.
Pellicori P; Joseph AC; Zhang J; Lukaschuk E; Sherwi N; Bourantas CV; Loh H; Clark AL; Cleland JG
Clin Res Cardiol; 2015 Nov; 104(11):935-45. PubMed ID: 25903113
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
Badar AA; Perez-Moreno AC; Hawkins NM; Jhund PS; Brunton AP; Anand IS; McKelvie RS; Komajda M; Zile MR; Carson PE; Gardner RS; Petrie MC; McMurray JJ
Circ Heart Fail; 2015 Jul; 8(4):717-24. PubMed ID: 26067854
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
Gandhi PU; Chow SL; Rector TS; Krum H; Gaggin HK; McMurray JJ; Zile MR; Komajda M; McKelvie RS; Carson PE; Januzzi JL; Anand IS
J Card Fail; 2017 Jan; 23(1):20-28. PubMed ID: 27317843
[TBL] [Abstract][Full Text] [Related]
17. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
Cunningham JW; Vaduganathan M; Claggett BL; John JE; Desai AS; Lewis EF; Zile MR; Carson P; Jhund PS; Kober L; Pitt B; Shah SJ; Swedberg K; Anand IS; Yusuf S; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2020 Aug; 8(8):618-626. PubMed ID: 32387067
[TBL] [Abstract][Full Text] [Related]
18. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
[TBL] [Abstract][Full Text] [Related]
19. Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients.
Kosztin A; Kutyifa V; Nagy VK; Geller L; Zima E; Molnar L; Szilagyi S; Ozcan EE; Szeplaki G; Merkely B
Europace; 2016 Apr; 18(4):550-9. PubMed ID: 26116830
[TBL] [Abstract][Full Text] [Related]
20. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.
Carson P; Massie BM; McKelvie R; McMurray J; Komajda M; Zile M; Ptaszynska A; Frangin G;
J Card Fail; 2005 Oct; 11(8):576-85. PubMed ID: 16230259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
